|
|
|
| Research on the Compulsory Licensing of Novel Coronavirus |
| Zhang Wujun,Zhang Bohan |
| (School of Humanities and Social Science,University of Science and Technology, Beijing 100083,China ) |
|
|
|
|
Abstract Since the early stage of the outbreak of the novel coronavirus , Remdeivir has receied extensive attentin, although it is still intrial , it brings a glimmer of hope to severe patients.Remdesivir is developed by Gilead company in the United States, and has made nearly perfect patent layout as early as in the research and development process.This paper first summarizes the compulsory license of drug patent and its characteristics, analyzes the current situation and existing problems of the compulsory license system of drug patent in China, draws lessons from the legislative practice of the compulsory license system of drug patent in foreign countries, proposes some suggestions, such as appropriately relax the restrictions of the applicant, appropriately expand the provisions of the application subject, make good use of the negotiation price of the compulsory license system of drug patent, and formulate the special license in line with the national conditions licensing system.
|
|
Received: 25 May 2020
|
|
|
|
|
|
| [1] 环球网.解读:新冠病毒疫情被列“国际关注的突发公共卫生事件”,会有哪些影响[EB/OL].(2020-01-31)[2020-01-31].https://world.huanqiu.com/article/9CaKrnKp7Ol.[2] 中国经济新闻网.历次国际关注的突发公共卫生事件概况及启示[EB/OL].（2020-02-14）[2020-02-14].http://www.cet.com.cn/wzsy/gysd/2481926.shtml.[3] 汉鼎好医友.瑞德西韦在美国获批紧急使用，治疗重症新冠肺炎患者[EB/OL].（2020-05-08）[2020-05-08].https://www.cn-healthcare.com/articlewm/20200508/content-1111191.html.[4] FOXNEWS.Remdesivir being used to treat coronavirus patients in Japan, health ministry says[EB/OL].（2020-05-14）[2020-05-14].https://www.foxnews.com/health/remdesivir-used-to-treat-coronavirus-patients-japan.[5] 新浪财经.“神药”瑞德西韦离患者还有多远[EB/OL].（2020-02-07）[2020-02-07].http://finance.sina.com.cn/wm/2020-02-07/doc-iimxyqvz1118562.shtml.[6] 国家知识产权局.《抗击新型冠状病毒肺炎专利信息研报》发布[EB/OL].（2020-02-14）[2020-02-14].http://www.cnipa.gov.cn/zscqgz/1145991.htm.[7] 张武军,韩愉东.创新驱动下专利运营法律问题研究[J].科技进步与对策,2016,33(24):104-108.[8] 中国科学院武汉病毒研究所.我国学者在抗2019新型冠状病毒药物筛选方面取得重要进展[EB/OL].（2020-02-04）[2020-02-04].http://www.whiov.ac.cn/kyjz_105338/202002/t20200204_5497136.html.[9] 快科技.美国吉利德就瑞德西韦声明:无偿提供药物 暂不考虑回报[EB/OL].（2020-02-09）[2020-02-09].https://tech.sina.com.cn/roll/2020-02-09/doc-iimxyqvz1490714.shtml.[10] 医谷.瑞德西韦将供应127国不含中国，同时在中国再启动一项临床试验[EB/OL].（2020-05-14）[2020-05-14].http://finance.sina.com.cn/stock/relnews/us/2020-05-14/doc-iircuyvi3105789.shtml.[11] 杨军.医药专利保护与公共健康的冲突研究[M].北京:北京大学出版社,2008.[12] 陈伟.甲型H1N1流感疫情与药品专利强制许可[J].中国发明与专利,2009(10):8-12.[13] 李昌凤.《TRIPS协定》药品专利强制许可制度的国际实践及我国的改革之路[J].创新科技,2018,18(10):76-79.[14] 易继明.专利的公共政策:以印度首个专利强制许可案为例[J].华中科技大学学报(社会科学版), 2014(2):76-82.[15] 游文亭.发展中国家药品专利权与公民健康权的博弈与平衡——以巴西和印度为例[J].电子知识产权,2018(7):38-47.[16] 李晓燕.药品专利限制与强制许可——基于国际经验与中国现况的评析[J].司法改革论评,2016 (2):394-412. |
|
|
|
